United Therapeutics Corp.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $783.3M | $781.5M | $790.2M | $799.5M | $798.6M | $794.4M | $735.9M | $748.9M |
| Cost of Revenue | $99.5M | $133.4M | $103.4M | $100.9M | $87.6M | $92.5M | $75.9M | $83.1M |
| Gross Profit | $683.8M | $648.1M | $686.8M | $698.6M | $711.0M | $701.9M | $660.0M | $665.8M |
| Gross Margin | 87.3% | 82.9% | 86.9% | 87.4% | 89.0% | 88.4% | 89.7% | 88.9% |
| Operating Expenses | ||||||||
| Research & Development | $146.3M | $138.2M | $139.5M | $127.5M | $134.0M | $149.0M | $133.8M | $103.5M |
| SG&A Expense | $206.7M | $184.1M | $190.6M | $182.6M | $212.5M | $170.1M | $168.5M | $219.2M |
| Operating Income | $330.8M | $325.8M | $356.7M | $388.5M | $364.5M | $382.8M | $357.7M | $343.1M |
| Operating Margin | 42.2% | 41.7% | 45.1% | 48.6% | 45.6% | 48.2% | 48.6% | 45.8% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $372.7M | $318.3M | $444.0M | $438.0M | $408.4M | $423.5M | $396.5M | $388.6M |
| Income Tax Expense | $39.7M | $43.4M | $79.7M | $99.3M | $98.9M | $101.3M | $95.2M | $79.5M |
| Net Income | $333.0M | $274.9M | $364.3M | $338.7M | $309.5M | $322.2M | $301.3M | $309.1M |
| Net Margin | 42.5% | 35.2% | 46.1% | 42.4% | 38.8% | 40.6% | 40.9% | 41.3% |
| EPS (Basic) | $7.82 | $6.32 | $8.36 | $7.73 | $6.86 | $7.18 | $6.73 | $6.93 |
| EPS (Diluted) | $7.27 | $5.82 | $7.66 | $7.16 | $6.41 | $6.63 | $6.23 | $6.39 |
| Shares Outstanding (Basic) | 42.6M | 43.5M | 44.3M | 43.8M | 45.1M | 44.9M | 45.2M | 44.6M |
| Shares Outstanding (Diluted) | 45.8M | 47.2M | 47.9M | 47.3M | 48.3M | 48.6M | 48.5M | 48.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |